Anti-CSF1R Antibody CDR Design for Specific Binding and Low Cross-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective monoclonal antibodies that specifically target human CSF-1R with high affinity and specificity, while minimizing cross-reactivity with related receptors and maintaining stability and functional efficacy.
Innovation Solution
Development of monoclonal antibodies with specific CDR sequences (SEQ ID NOs: 1-60) that bind to human CSF-1R, exhibiting high affinity (KD < 40 nM), stability, and functional inhibition of CSF-1R phosphorylation and monocyte proliferation, with minimal cross-reactivity to mouse CSF-1R and enhanced stability under various conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If monoclonal antibodies are developed to target human CSF-1R, then binding affinity and specificity to human CSF-1R is improved, but cross-reactivity with related receptors may increase
Solution Approach 1:
The antibody design focuses on creating CDR regions with specific local properties that recognize unique epitopes on human CSF-1R. The variable regions are engineered to have precise binding characteristics that differentiate human CSF-1R from related receptors, achieving high specificity while minimizing cross-reactivity through localized optimization of binding interfaces.
Solution Approach 2:
The patent employs systematic optimization of antibody parameters including affinity (KD < 40 nM), specificity, and cross-reactivity profiles. By adjusting CDR sequences and performing iterative selection processes, the antibody parameters are tuned to achieve optimal binding to human CSF-1R while maintaining minimal cross-reactivity with related receptors.
2Reliability
If antibody affinity for CSF-1R is increased, then functional inhibition of phosphorylation is improved, but antibody stability may be compromised
Solution Approach 1:
The antibody undergoes systematic parameter optimization where affinity, stability, and functional efficacy are adjusted simultaneously. The CDR sequences are engineered to achieve high affinity (KD < 40 nM) for CSF-1R while maintaining structural stability through controlled selection processes that balance binding strength with molecular stability under various conditions.
Solution Approach 2:
The antibody design incorporates stability-enhancing features from the outset to prevent potential instability issues. The variable and constant regions are configured to maintain structural integrity even at high affinity binding states, providing a buffer against potential destabilization while achieving strong functional inhibition of CSF-1R phosphorylation.
3Reliability
If monoclonal antibodies are engineered for high specificity, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes phage display technology to create and screen large libraries of antibody variants, efficiently copying and selecting optimal sequences from a diverse pool. This high-throughput copying and selection approach enables the identification of antibodies with high specificity and therapeutic efficacy while streamlining the manufacturing process through standardized library construction and selection protocols.
Solution Approach 2:
The antibody design employs universal framework regions and standardized constant regions that can be produced using common manufacturing platforms. By separating the specific CDR regions (which provide therapeutic efficacy) from the standardized framework regions (which facilitate manufacturing), the patent achieves high specificity antibodies through a streamlined, multi-functional development approach.
Data Source
AI summary
The disclosure relates to antibodies against human CSF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.